The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.
BACKGROUND: The TP53 Arg72Pro polymorphism encodes two p53 variants with different biochemical properties. Here we investigated the impact of this polymorphism on the expression of key p53 target genes in a panel of human breast carcinomas, breast cancer risk, and age at onset. METHODOLOGY/PRINCIPAL...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3468577?pdf=render |
| _version_ | 1819266033521786880 |
|---|---|
| author | Katharina Proestling Alexandra Hebar Nina Pruckner Erika Marton Ursula Vinatzer Martin Schreiber |
| author_facet | Katharina Proestling Alexandra Hebar Nina Pruckner Erika Marton Ursula Vinatzer Martin Schreiber |
| author_sort | Katharina Proestling |
| collection | DOAJ |
| description | BACKGROUND: The TP53 Arg72Pro polymorphism encodes two p53 variants with different biochemical properties. Here we investigated the impact of this polymorphism on the expression of key p53 target genes in a panel of human breast carcinomas, breast cancer risk, and age at onset. METHODOLOGY/PRINCIPAL FINDINGS: The Arg72Pro polymorphism was genotyped in 270 breast cancer patients and 221 control subjects. In addition, the Arg72Pro genotype of 116 breast tumors was determined, and correlated with intratumoral mRNA expression of TP53 and its key target genes MDM2, p21, BAX, and PERP, as quantified by qRT-PCR. We found a significantly increased breast cancer risk associated with the Pro-allele (per-allele odds ratio, 1.46; 95% confidence interval, 1.08-1.99), and a significantly later mean age at breast cancer onset for Pro/Pro patients (63.2±18 years) compared to Arg/Arg patients (58.2±15 years). The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. The median mRNA levels of p21 and BAX in the tumors of Pro-allele carriers were significantly reduced to 55.7% and 76.9% compared to Arg/Arg patients, whereas p53, MDM2 and PERP expression were hardly altered. CONCLUSIONS/SIGNIFICANCE: The p53(72Arg) variant appears to be a more potent in vivo transcription factor and tumor suppressor in human breast cancer than the p53(72Pro) variant. The Arg72Pro genotype has no significant effects in patients with TP53 mutated tumors, in which p53 is non-functional. |
| first_indexed | 2024-12-23T20:54:50Z |
| format | Article |
| id | doaj.art-426a256e0abf47bf823e5e2af510f2d9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T20:54:50Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-426a256e0abf47bf823e5e2af510f2d92022-12-21T17:31:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01710e4732510.1371/journal.pone.0047325The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.Katharina ProestlingAlexandra HebarNina PrucknerErika MartonUrsula VinatzerMartin SchreiberBACKGROUND: The TP53 Arg72Pro polymorphism encodes two p53 variants with different biochemical properties. Here we investigated the impact of this polymorphism on the expression of key p53 target genes in a panel of human breast carcinomas, breast cancer risk, and age at onset. METHODOLOGY/PRINCIPAL FINDINGS: The Arg72Pro polymorphism was genotyped in 270 breast cancer patients and 221 control subjects. In addition, the Arg72Pro genotype of 116 breast tumors was determined, and correlated with intratumoral mRNA expression of TP53 and its key target genes MDM2, p21, BAX, and PERP, as quantified by qRT-PCR. We found a significantly increased breast cancer risk associated with the Pro-allele (per-allele odds ratio, 1.46; 95% confidence interval, 1.08-1.99), and a significantly later mean age at breast cancer onset for Pro/Pro patients (63.2±18 years) compared to Arg/Arg patients (58.2±15 years). The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. The median mRNA levels of p21 and BAX in the tumors of Pro-allele carriers were significantly reduced to 55.7% and 76.9% compared to Arg/Arg patients, whereas p53, MDM2 and PERP expression were hardly altered. CONCLUSIONS/SIGNIFICANCE: The p53(72Arg) variant appears to be a more potent in vivo transcription factor and tumor suppressor in human breast cancer than the p53(72Pro) variant. The Arg72Pro genotype has no significant effects in patients with TP53 mutated tumors, in which p53 is non-functional.http://europepmc.org/articles/PMC3468577?pdf=render |
| spellingShingle | Katharina Proestling Alexandra Hebar Nina Pruckner Erika Marton Ursula Vinatzer Martin Schreiber The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS ONE |
| title | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. |
| title_full | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. |
| title_fullStr | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. |
| title_full_unstemmed | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. |
| title_short | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. |
| title_sort | pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of bax and p21 and increased breast cancer risk |
| url | http://europepmc.org/articles/PMC3468577?pdf=render |
| work_keys_str_mv | AT katharinaproestling theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT alexandrahebar theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT ninapruckner theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT erikamarton theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT ursulavinatzer theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT martinschreiber theproalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT katharinaproestling proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT alexandrahebar proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT ninapruckner proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT erikamarton proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT ursulavinatzer proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk AT martinschreiber proalleleofthep53codon72polymorphismisassociatedwithdecreasedintratumoralexpressionofbaxandp21andincreasedbreastcancerrisk |